Key points are not available for this paper at this time.
In this paper, it was carried out a comprehensive study of the positions of innovative drugs in the Russian pharmaceutical market. Authors identified key barriers for developers of original drugs to receive marketing authorization in Russia. They analyzed share of drugs with new active ingredients in the total number of authorized drugs over 10 years, as well as the role of domestic developers. The leading role of transnational pharmaceutical corporations in the introduction of original drugs to the Russian market have been shown. In accordance with the presented data, brief recommendations have been given for improving the regulatory framework in the field of the development and marketing authorization of innovative drugs.
Чапленко et al. (Wed,) studied this question.